
Shares of U.S. drugmaker Eli Lilly LLY.N rise 2% to $859.99 premarket
Co forecasts 2025 EPS between $22.50 and $24.00, above Street estimates of $22.86 at midpoint, according to data compiled by LSEG
Co posts Q4 adj EPS of $5.32 vs estimates of $4.95, according to data compiled by LSEG
Q4 sales of weight-loss drug Zepbound came in at $1.91 billion vs estimates of $2.03 billion -LLY
Up to last close, stock gained 19.5% in the past 12 months